Dr. Sandeep Kumar Nadendla, PhD

Founder & Chief Executive Officer / Chief Scientific Officer (CEO & CSO), Ipseity Bio

Dr. Sandeep Kumar Nadendla is a molecular biologist, translational researcher, and clinical diagnostics expert with extensive experience in advanced research, laboratory operations, and diagnostic innovation across the United States and internationally. As the Founder, CEO, and Chief Scientific Officer of Ipseity Bio, he leads the organization’s scientific strategy, innovation roadmap, and vision to develop transformative diagnostic technologies for infectious, chronic, and precision-medicine applications. With a strong foundation in molecular biology, genomics, immunology, and clinical diagnostics, Dr. Nadendla is recognized for his leadership in building high-complexity molecular laboratories, designing advanced diagnostic assays, and driving translational research that bridges scientific discovery with real-world clinical impact.

Experience: 15+ Years

Experience & Leadership

Dr. Nadendla has led scientific, operational, and diagnostic programs across both academic and clinical environments. In the United States, he has overseen high-complexity molecular testing within CLIA-certified laboratories, ensuring excellence in assay validation, workflow optimization, regulatory compliance, and quality systems. He has served as a Molecular Technical Consultant for multiple clinical laboratories nationwide, guiding teams in molecular assay development, lab expansion, and readiness for CLIA and CAP inspections. As the Founder of Ipseity Diagnostics, LLC in Houston, he established a clinical diagnostics laboratory specializing in infectious disease testing, pharmacogenomics, and genomic medicine. At Ipseity Bio, he leads multidisciplinary teams developing innovative solutions in genomics, proteomics, artificial intelligence, and translational biotechnology, advancing the company’s mission to enable precision diagnostics and data-driven healthcare globally.

Awards & Key Contributions

Dr. Nadendla's contributions span molecular diagnostics, translational research, and laboratory innovation. He has played a pivotal role in developing advanced PCR-based diagnostics, optimizing infectious disease testing workflows, and enhancing molecular laboratory infrastructures across regions. His scientific work in cancer biology, inflammatory pathways, and biomarker discovery has been featured in respected peer-reviewed journals. As a consultant and laboratory leader, he has supported the modernization of multiple clinical labs in the United States, enabling rapid, high-quality diagnostic services for diverse patient populations. Through his entrepreneurial leadership at Ipseity Bio and Ipseity Diagnostics, he continues to drive innovation at the intersection of molecular science, technology, and global health, contributing to improvements in diagnostic accuracy, healthcare delivery, and translational medicine.

Expertise

Molecular Biology & Translational Research
Clinical Diagnostics & Laboratory Leadership (CLIA Labs)
PCR, qPCR, Multiplex Assays & Molecular Test Development
Genomics, Proteomics & Biomarker Discovery
Immunology, Cell Signaling & Molecular Pathology
Clinical Laboratory Compliance & Quality Systems
Infectious Disease Diagnostics & Public Health Testing
AI-integrated Diagnostics & Data-driven Healthcare Innovation
Molecular Technical Consulting & Laboratory Scaling

Education

PhD in Molecular Biology (Cell Signaling, Immunology & Molecular Pathology)
Advanced research training in genomics, proteomics, and biomarker discovery
Specialized training in molecular diagnostics, assay development & clinical laboratory operations
Scientific research contributions published in leading peer-reviewed journals